Task D07: GLP 28-day repeat toxicology and cardiovascular telemetry assessment of Lassa antiviral in cynomolgus macaques
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 272201800001I-0-759302100007-1
Grant search
Key facts
Disease
Lassa Haemorrhagic FeverStart & end year
20212022Known Financial Commitments (USD)
$1,766,053Funder
National Institutes of Health (NIH)Principal Investigator
JON MIRSALISResearch Location
United States of AmericaLead Research Institution
SRI INTERNATIONALResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
Innovation
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.